Volume 20, Number 5—May 2014
Research
Streptococcus mitis Strains Causing Severe Clinical Disease in Cancer Patients
Samuel A. Shelburne
, Pranoti Sahasrabhojane, Miguel Saldana, Hui Yao, Xiaoping Su, Nicola Horstmann, Erika Thompson, and Anthony R. Flores
, Pranoti Sahasrabhojane, Miguel Saldana, Hui Yao, Xiaoping Su, Nicola Horstmann, Erika Thompson, and Anthony R. Flores
Table 3
Relative virulence of viridans group streptococci strains in a neutropenic mouse model*
| Strain | Streptococcus mitis cluster | Pitt bacteremia score of infected patient | LD50 |
|---|---|---|---|
| SVGS004 | 3 | 1 | 4.1 × 105 |
| SVGS006 | 2 | 2 | 1.6 × 106 |
| SVGS016 | 2 | 1 | 1.4 × 105 |
| SVGS019 | 1 | 3 | 1.9 × 104 |
| SVGS031 | 2 | 1 | 3.6 × 105 |
*SVGS, Shelburne viridans group streptococcus; LD50, considered, for the purpose of this study, to be the dose at which 50% of the animals nearly died.
Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.